Fatal pulmonary toxicity resulting from treatment with gemcitabine.
about
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.Antimetabolites and cancer: emerging data with a focus on antifolates.Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised hostDifferential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.A case of late-onset gemcitabine lung toxicityWeekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.Gemcitabine-induced severe pulmonary toxicity.Pulmonary toxicity from novel antineoplastic agents.Role of gemcitabine in cancer therapy.Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.Inhaled chemotherapy in lung cancer: future concept of nanomedicine.Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan.Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.Severe interstitial pneumonitis associated with docetaxel administration.Gemcitabine-induced chronic systemic capillary leak syndromeGemcitabine-induced extensive skin necrosis.Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates.Gemcitabine-associated diffuse alveolar hemorrhage.Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report.Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
P2860
Q33293437-2330F30E-4C12-4D4E-B5AF-9ED6E44CE938Q33337520-94B587EC-5334-4E4E-BA61-CED64455B33BQ33344553-A643A571-2420-4B72-BB17-7D64365F3A65Q33402203-D19AAA72-6EEB-4931-9C02-4C6D85867D81Q33530405-A901ACD0-1918-49B7-B8EE-82FC139CD512Q33891037-45B502F2-6FAA-4810-8052-B13913E6363BQ33922242-2AE9F05D-6CE4-4686-99FE-F5FBBAF9B3C7Q34155353-38AE1815-5E27-4140-8D74-E035D2143141Q34626688-4A7679DA-4FAC-4AA7-9803-B31C1109FA57Q34810756-188CCA81-5F28-4922-B23F-B96675A2D808Q35038451-34F3E195-33C0-41ED-9931-8373D6C21407Q35052548-28047359-930E-4238-AB42-4A2B6ECAF4EDQ35375610-9F78EC1D-EE21-427D-8A7A-6125BE5B0FC0Q35641366-E2F36A74-FF7E-433D-AF6E-D43CDB031465Q36314452-D4819B66-ADE6-43CC-B449-DE3FF2FEFDECQ36429373-3CB4204A-8CFB-4430-B21D-5CD193D0A611Q37973172-3B7FED76-28BC-4002-BDFF-549EA9399683Q38012447-6C9B4C9F-7331-48C1-946B-B55523D96B79Q39769492-3E5A5073-655B-4863-8856-1881ADAF8D11Q40099115-05E7898B-AC27-4F9A-9A11-3E623C058A4FQ40569185-4C705FC2-3965-4795-AAA7-FB6B8B5226C8Q40588005-FB9E3A5A-F81E-43C8-8F80-4D590822297FQ41578489-156D5F4F-0907-4DCB-818D-884ACB172912Q42170009-9BE2F45A-58A3-455F-BE10-BCE7CD5691E0Q42225847-2ADCE822-BC85-43ED-8805-A3287DF4A687Q42278411-9089EE89-91C7-40C6-925C-30D5E676DAA6Q42948553-245CB54A-8EFC-4144-BD86-30B868257710Q43078253-6262E449-3EBD-43AC-8915-F7E52E2631BBQ43104543-87CFDA5D-87BB-4070-AFB4-F5F49D7DACF6Q43783771-7A818BEB-D944-4A86-83DD-28D1BA341F49Q43945172-C19485C7-A381-453C-86FD-63119923478DQ44227691-EFA52947-B2BD-434C-9860-A2DF1453272CQ44516860-7E1C9638-E5EC-4CE5-8A33-444E8A4B5CE5Q44906700-CE981E7E-FA85-4EA1-AAD4-3B41E34AE591Q46495643-5DDD2484-AAB8-49A0-ABF0-8FC1CD459B7CQ51696169-73FDBD8E-BEBB-41CF-84F6-47BB8A00F58CQ52978070-206F1E00-5AEE-434E-95D1-2C8CBDF53767
P2860
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
@en
type
label
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
@en
prefLabel
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
@en
P2093
P2860
P1433
P1476
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q
P407
P577
1997-07-01T00:00:00Z